Skip to content

Psoriasis Stratification to Optimise Relevant Therapy

The vision of the PSORT consortium is to better understand the determinants of response of psoriasis to biologic therapies. By collaboration with our partners from industry we will develop a clinical test to predict response and thereby rationalise and optimise patient care in a cost-effective manner. Associated projects and campaigns. Click on the links below to access additional related content. Psoriasis Stratification to Optimise Relevant Therapy (PSORT). A moving poem written by a person with psoriasis has been turned into a film by Manchester’s Psoriasis Shout Out initiative, to raise awareness of the inflammatory skin condition on World Psoriasis Day (29 October).

Psoriasis Stratification to Optimise Relevant Therapy 2Global Prospective Pediatric Psoriasis Registry Project. Psoriasis Stratification to Optimise Relevant Therapy (PSORT). Systemic Therapy Working Group. The benefits were maintained for several months after the therapy ended, and this type of treatment has been adopted into widespread clinical practice across the UK. Psoriasis Stratification to Optimise Relevant Therapy. Thus, for example, a stratified medicine initiative: the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium was recently established in the UK to better understand the determinants of response of psoriasis to biological therapies (5).

Addendum – Effectiveness of biologics in psoriasis: application of Bayesian models of network meta-analysis. (5) The Psoriasis Stratification to Optimise Relevant Therapy (PSORT): About PSORT. If you have psoriasis, or if you know someone who does, then this site is for you. With approved drugs we already have the ability to treat psoriasis very well, and probably better than just about any autoimmune disease, says James Krueger, who studies inflammatory skin diseases at Rockefeller University in New York. The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) programme, funded with 5m from the UK Medical Research Council and 2m from the pharmaceutical industry, plans to undertake detailed studies of the genetics, transcriptomics, immunology, pharmacology, clinical data and treatment adherence of patients with chronic plaque psoriasis who receive biologic therapies, and correlate these with treatment outcomes.

Program Supporters

Research Associate in Psoriasis Biomarker Discovery in the Department of Medical, Molecular Genetics.

Newer Agents For Psoriasis In Adults